id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2022-0051-0004,DEA,DEA-2022-0051,Ganaxolone eight factor_DEA,Supporting & Related Material,,2022-11-09T05:00:00Z,2022,11,,,2022-11-09T16:41:53Z,,0,0,090000648549e073
DEA-2022-0051-0003,DEA,DEA-2022-0051,Ganaxolone 8FA,Supporting & Related Material,,2022-11-09T05:00:00Z,2022,11,,,2022-11-09T16:41:43Z,,0,0,090000648549e072
DEA-2022-0051-0002,DEA,DEA-2022-0051,Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V,Rule,,2022-11-09T05:00:00Z,2022,11,2022-11-09T05:00:00Z,,2022-11-09T16:24:54Z,2022-24157,0,0,090000648549cc67
DEA-2022-0051-0001,DEA,DEA-2022-0051,Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V,Rule,,2022-06-01T04:00:00Z,2022,6,2022-06-01T04:00:00Z,2022-07-02T03:59:59Z,2022-06-01T16:56:42Z,2022-11735,0,0,090000648511e3a9